Literature DB >> 23846244

Objective: tumor. Strategies of drug targeting at the tumor mass level.

C Martín Sabroso1, A I Torres-Suárez.   

Abstract

Concurrent with the development of new antitumor drugs, there is intensive research to develop strategies and systems to optimize the efficacy of well-known anticancer agents. The main research lines are: (a) reduction in toxicity, (b) improvement of administration and (c) overcoming drug resistance. Drug targeting systems allow us to act on these three points. The best way to increase efficacy and reduce toxicity of an anticancer agent is targeting the drug at the level of the tumor masses and maintaining its concentration there for enough time to optimize its therapeutic action. Numerous strategies have been developed to achieve this second order targeting, based on the use of polymeric-drug conjugates, polymeric micelles, liposomes and albumin conjugates and nanoparticles, whose main features of toxicity, efficacy and administration are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846244     DOI: 10.1007/s12094-013-1075-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  45 in total

Review 1.  Microtubule-targeted anticancer agents and apoptosis.

Authors:  Kapil N Bhalla
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

Review 2.  Impact of albumin on drug delivery--new applications on the horizon.

Authors:  Bakheet Elsadek; Felix Kratz
Journal:  J Control Release       Date:  2011-09-16       Impact factor: 9.776

3.  Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.

Authors:  María J Vicent; Francesca Greco; Robert I Nicholson; Alison Paul; Peter C Griffiths; Ruth Duncan
Journal:  Angew Chem Int Ed Engl       Date:  2005-06-27       Impact factor: 15.336

4.  The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.

Authors:  T D Madden; P R Harrigan; L C Tai; M B Bally; L D Mayer; T E Redelmeier; H C Loughrey; C P Tilcock; L W Reinish; P R Cullis
Journal:  Chem Phys Lipids       Date:  1990-03       Impact factor: 3.329

5.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors:  William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

Review 6.  Role of pegylated liposomal doxorubicin in ovarian cancer.

Authors:  J Tate Thigpen; Carol A Aghajanian; David S Alberts; Susana M Campos; Alan N Gordon; Maurie Markman; D Scott McMeekin; Bradley J Monk; Peter G Rose
Journal:  Gynecol Oncol       Date:  2005-01       Impact factor: 5.482

Review 7.  Novel therapeutic agents in ovarian cancer.

Authors:  R Agarwal; M Linch; S B Kaye
Journal:  Eur J Surg Oncol       Date:  2006-05-15       Impact factor: 4.424

8.  Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

Authors:  M R Ranson; J Carmichael; K O'Byrne; S Stewart; D Smith; A Howell
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

9.  INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.

Authors:  R Graeser; N Esser; H Unger; I Fichtner; A Zhu; C Unger; F Kratz
Journal:  Invest New Drugs       Date:  2009-01-08       Impact factor: 3.850

Review 10.  Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.

Authors:  Qiang Fu; Jin Sun; Wenping Zhang; Xiaofan Sui; Zhongtian Yan; Zhonggui He
Journal:  Recent Pat Anticancer Drug Discov       Date:  2009-11       Impact factor: 4.169

View more
  1 in total

1.  Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer.

Authors:  Longlong Tian; Qian Chen; Xuan Yi; Guanglin Wang; Jie Chen; Ping Ning; Kai Yang; Zhuang Liu
Journal:  Theranostics       Date:  2017-01-12       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.